AI
CLYM

Atom Investors’s Climb Bio CLYM Stock Holding History

Atom Investors’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-78,276
Closed -$214K – 702
2024
Q1 		$214K Hold
78,276
– – 0.03% 475
2023
Q4 		$211K Sell
78,276
-610
-0.8% -$1.59K 0.04% 401
2023
Q3 		$207K Hold
78,886
– – 0.05% 373
2023
Q2 		$221K Hold
78,886
– – 0.08% 232
2023
Q1 		$229K Buy
78,886
+3,235
+4% +$11.1K 0.12% 187
2022
Q4 		$278K Buy
75,651
+8,577
+13% +$25.4K 0.14% 145
2022
Q3 		$217K Buy
67,074
+40,765
+155% +$130K 0.08% 206
2022
Q2 		$79K Buy
+26,309
New +$124K 0.03% 225

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Atom Investors's CLYM Position: Q2 2024 in Review

Atom Investors sold out of Climb Bio (CLYM) in Q2 2024, closing a stake of 78,276 shares — an estimated $214K sold.

Atom Investors first reported a position in CLYM in Q2 2022 and held it in 8 quarters. The position peaked at $278K in Q4 2022. 47 funds tracked by Wall St. Rank hold CLYM as of Q2 2024.

  • Atom Investors reported no remaining Climb Bio position as of Q2 2024 after selling out during the quarter.
  • Atom Investors sold 78,276 Climb Bio shares in Q2 2024, an estimated $214K.
  • Atom Investors first reported a position in Climb Bio in Q2 2022 and held it in 8 quarters.
  • Atom Investors's Climb Bio position peaked at $278K in Q4 2022.
  • 47 funds tracked by Wall St. Rank held Climb Bio as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.